Atherosclerosis susceptibility gene locus 1 (Athsq1) and atherosclerosis susceptibility gene locus 2 (Athsq2)
AssigneeThe Trustees of Columbia University in the City of New York
InventorsAlan R. Tall, Carrie L. Welch, Chien-Ping Liang
Life of this patent
Estimating the term…
Abstract
This invention provides isolated nucleic acids encoding mammalian membrane-bound and soluble LOX-1 receptors. The invention also provides methods of identifying agents that inhibit the activity of a mammalian LOX-1 receptor. This invention further provides methods of preventing or treating atherosclerosis, heart disease or stroke in a subject which comprise reducing the activity of membrane-bound LOX-1 receptor.
Claims36
An isolated nucleic acid encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 14, SEQ ID NO:
- 16, SEQ ID NO:
- 18, SEQ ID NO:
- 22, SEQ ID NO:
- 24, and SEQ ID NO:
- 26.
A nucleic acid probe of at least about 15 nucleotides in length which specifically hybridizes with a nucleic acid encoding a mammalian LOX-1 receptor or with a nucleic acid having the complementary sequence thereof.
An isolated protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 14, SEQ ID NO:
- 16, SEQ ID NO:
- 18, SEQ ID NO:
- 22, SEQ ID NO:
- 24, and SEQ ID NO:
- 26.
A method of determining whether an agent inhibits the activity of a membrane-bound mammalian LOX-1 receptor, which comprises (a) contacting the agent with the receptor under conditions which would permit the inhibition of such activity by an activity-inhibiting agent, and (b) detecting whether the agent has inhibited the activity of the LOX-1 receptor.
A method of inhibiting the activity of a mammalian LOX-1 receptor, which comprises contacting the receptor with an agent that inhibits the activity of a mammalian LOX-1 receptor.
A method of reducing the amount of a mammalian LOX-1 receptor on the surface of a cell, which comprises delivering to the cell an agent that reduces the expression of mammalian LOX-1 receptor therein.
A method of inhibiting the ability of an agent to bind to and activate a membrane-bound mammalian LOX-1 receptor, which comprises contacting the agent with a soluble mammalian LOX-1 receptor.
A method of treating a mammalian subject afflicted with a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of LOX-1 receptors in the subject.
A method of inhibiting the onset in a mammalian subject of a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a prophylactically effective amount of an agent that inhibits the activity of LOX-1 receptors in the subject.
A method of treating a mammalian subject afflicted with a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the expression of LOX-1 receptors in the subject's cells.
A method of inhibiting the onset in a mammalian subject of a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a prophylactically effective amount of an agent that inhibits the expression of LOX-1 receptors in the subject's cells.
A method of treating a mammalian subject afflicted with a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a therapeutically effective amount of a soluble LOX-1 receptor.
A method of inhibiting the onset in a mammalian subject of a disorder selected from the group consisting of atherosclerosis, heart failure and stroke, comprising administering to the subject a prophylactically effective amount of a soluble LOX-1 receptor.
Dependencies are inferred from the claim text.